Qualigen
Company

Last deal

$8.82M

Amount

Post-IPO Equity

Stage

29.11.2021

Date

3

all rounds

$30.82M

Total amount

date founded

Financing round

General

About Company
Qualigen is a biotech company focused on cancer and infectious disease treatments, as well as diagnostic platforms.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1996

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The NASDAQ-listed Qualigen is dedicated to developing innovative therapeutic products to treat both adult and pediatric cancers, which could potentially receive Orphan Drug Designation. Additionally, the company is expanding its FastPack® diagnostic platform, which provides rapid and accurate results for a range of medical conditions. With a strong focus on improving patient outcomes, Qualigen is a leading player in the biotech industry.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Prometheus Biosciences

Prometheus Biosciences

Prometheus Biosciences develops precision therapeutics and diagnostics for IBD.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

San Diego, CA, USA

total rounds

6

total raised

$951.84M
CNCure biotech

CNCure biotech

CNCure is a biotechnology company that specializes in drug development and cancer therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Hwasun-gun, Jeollanam-do, South Korea

total rounds

1
Sapphire Biotech

Sapphire Biotech

Sapphire Biotech develops cancer therapeutics and diagnostics for global cancer care.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

San Diego, CA, USA
Cizzle Biotech Ltd.

Cizzle Biotech Ltd.

Cizzle Biotech develops therapies for lung cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

York, UK

total rounds

3

total raised

$853.38K

Financials

Funding Rounds
4
3

Number of Funding Rounds

$30.82M

Money Raised

Their latest funding was raised on 29.11.2021. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
29.11.2021
$8.82M
04.08.2020
$10M
13.07.2020
$8M
Co-Investors
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
Nanosynex acquired by Qualigen

Nanosynex acquired by Qualigen

acquirer

Qualigen
Qualigen

date

03.05.2022

type

Acquisition
Nanosynex

Nanosynex

NanoSynex develops diagnostic tests that check bacterial resistance to antibiotics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Tel Aviv-Yafo, Israel

total rounds

2

total raised

$83.35K
Ritter Pharmaceuticals acquired by Qualigen

Ritter Pharmaceuticals acquired by Qualigen

acquirer

Qualigen
Qualigen

date

26.05.2020
Ritter Pharmaceuticals

Ritter Pharmaceuticals

Ritter Pharmaceuticals develops therapeutic products to treat gastrointestinal diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Manufacturing

Location

Los Angeles, CA, USA

total rounds

10

total raised

$25.73M

People

Founders
1
Michael S. Poirier
Michael S. Poirier

Michael S. Poirier

Michael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer. Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry. From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina. EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry. From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System. This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide. From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems. Both IMx and later, AxSym, became the leaders in their respective markets. Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.

current job

Qualigen
Qualigen

organization founded

1

Michael S. Poirier

Employee Profiles
7
Benedict M. Abugan

Benedict M. Abugan

Vice President, Head of Diagnostics and Corporate Communications

Shishir Sinha

Shishir Sinha

Sr. Vice President & Chief Operating Officer

Tariq Arshad

Tariq Arshad

Chief Medical Officer, Senior Vice President

Amy Broidrick

Executive Vice President & Chief Strategy Officer

Christopher L. Lotz

Christopher L. Lotz

VP & Chief Financial Officer

Michael S. Poirier

Michael S. Poirier

Founder ,President, CEO & Chairman

Activity

Recent News
1